Awakn Successfully Completes Phase One Of Its Drug Discovery Program

Awakn Life Sciences has announced the successful completion of phase one of its new chemical entity (NCE) development program, strengthening Awakn’s pipeline for the treatment of a broad range of both substance and behavioural addictions.Β 

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

πŸ“° Weekly newsletter about the psychedelic research

βœ”οΈ Unlimited access to our database and original articles

πŸ–ŠοΈ Add (private) notes and comments to each page

Make an account
Category Press Release
Published in Awakn Life Sciences

Companies Featured

Awakn Life Sciences
AWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.

Inline Feedbacks
View all comments